Our findings underscoring the potential role of RNF43 in modulating response to anti-BRAF/EGFR therapy point to an interplay between the MAPK and WNT signaling pathways in MSS-mCRCBRAF-V600E tumors. This evidence concerns the gene EGFR and Marinesco-Sjogren syndrome.